The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price has fallen 40% in a year, to $0.0009 per unit — and generics that get this cheap tend to get abandoned rather than defended. It is in shortage right now — FDA lists the reason as “demand increase for the drug”. A Class II recall hit this product in the past year (Baxter Healthcare Corporation). One of its named manufacturing plants, Baxter Healthcare Corporation, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.